XML 52 R5.htm IDEA: XBRL DOCUMENT v2.4.0.8
Condensed Consolidated Statements of Cash Flows (Unaudited) (USD $)
In Thousands, unless otherwise specified
9 Months Ended
Sep. 30, 2014
Sep. 30, 2013
Operating activities    
Net loss $ (29,165) $ (17,240)
Adjustments to reconcile net loss to net cash (used in) provided by operating activities:    
Noncash benefit on release of tax valuation allowance (11,797)  
Depreciation and amortization 2,558 610
Stock-based compensation expense 7,757 4,833
Remeasurement of contingent consideration 78  
Issuance of restricted common stock in exchange for consulting services to non-employees 168  
Re-measurement of warrants   440
Loss on disposal of equipment 1 2
Other non-cash items 77  
Changes in operating assets and liabilities:    
Prepaid expenses and other assets 166 (3,903)
Accounts payable (2,604) (1,021)
Accrued expenses and other liabilities 5,613 1,248
Deferred revenue (19,005) 61,203
Deferred rent 2,124 2,733
Net cash (used in) provided by operating activities (44,029) 48,905
Investing activities    
Restricted cash 209 (1,153)
Purchase of property and equipment (6,303) (3,380)
Purchases of marketable securities (174,021)  
Acquisition of business, net of cash acquired (4,673)  
Net cash used in investing activities (184,788) (4,533)
Financing activities    
Proceeds from public offering of common stock, net of issuance costs 109,766 104,972
Repayment of nonrecourse note collateralized by restricted stock   344
Proceeds from exercise of stock options and issuance of common stock 2,375 92
Net cash provided by financing activities 112,141 105,408
(Decrease) increase in cash and cash equivalents (116,676) 149,780
Cash and cash equivalents at beginning of period 206,279 67,011
Cash and cash equivalents at end of period 89,603 216,791
Non-cash investing and financing activities:    
Purchases of property and equipment included in accounts payable and accrued expenses 1,298 1,347
Reclassification of warrants to additional paid-in capital   655
Conversion of preferred stock to common stock upon closing of IPO   122,177
Stock option exercise proceeds receivable $ 223